Cell biology, TSC1, TSC2, Genetics and Tuberous sclerosis are his primary areas of study. His work is dedicated to discovering how Cell biology, Molecular biology are connected with Cell growth and other disciplines. His TSC1 study combines topics in areas such as mTORC1, Heterozygote advantage, Neuroscience and Sirolimus.
As a member of one scientific family, David J. Kwiatkowski mostly works in the field of TSC2, focusing on Cancer research and, on occasion, Protein kinase B, CDKN2A, Chromophobe cell, Carcinoma and Germline mutation. His Tuberous sclerosis research also works with subjects such as
David J. Kwiatkowski focuses on Cancer research, Tuberous sclerosis, Genetics, TSC1 and Internal medicine. His work focuses on many connections between Cancer research and other disciplines, such as PI3K/AKT/mTOR pathway, that overlap with his field of interest in Sirolimus and Protein kinase B. David J. Kwiatkowski works mostly in the field of TSC1, limiting it down to topics relating to TSC2 and, in certain cases, Germline mutation and Tumor suppressor gene, as a part of the same area of interest.
The various areas that David J. Kwiatkowski examines in his Internal medicine study include Endocrinology and Oncology. His work in Gene addresses subjects such as Molecular biology, which are connected to disciplines such as Cell biology and Exon. His Lung cancer study combines topics from a wide range of disciplines, such as KRAS and Adenocarcinoma.
His primary areas of investigation include Cancer research, Internal medicine, Oncology, Tuberous sclerosis and TSC1. His work deals with themes such as Cell growth, mTORC1, PI3K/AKT/mTOR pathway, Mutation and Renal cell carcinoma, which intersect with Cancer research. His research in Internal medicine intersects with topics in Somatic cell, ARID1A and Medical genetics.
His Oncology research is mostly focused on the topic Lung cancer. His Tuberous sclerosis research is under the purview of Pathology. His TSC1 research is multidisciplinary, incorporating perspectives in Subependymal zone, Kidney Angiomyolipoma, Angiomyolipoma, Microphthalmia-associated transcription factor and TSC2.
David J. Kwiatkowski mainly investigates Oncology, Internal medicine, Cancer research, Tuberous sclerosis and Lung cancer. His work in the fields of Internal medicine, such as Urothelial carcinoma, intersects with other areas such as Hepatocyte Growth Factor Receptor. The Cancer research study combines topics in areas such as Mutation, Cancer, Renal cell carcinoma and Chromophobe Renal Cell Carcinoma.
His research integrates issues of Autism, TSC2, TSC1 and Epilepsy in his study of Tuberous sclerosis. TSC2 is a primary field of his research addressed under PI3K/AKT/mTOR pathway. David J. Kwiatkowski has researched Lung cancer in several fields, including Fluorescence in situ hybridization, Guideline, Molecular pathology and KRAS.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Comprehensive molecular profiling of lung adenocarcinoma: The cancer genome atlas research network
Eric A. Collisson;Joshua D. Campbell;Angela N. Brooks;Angela N. Brooks;Alice H. Berger.
Comprehensive molecular characterization of urothelial bladder carcinoma
John N Weinstein;Rehan Akbani;Bradley McIntosh Broom;Wenyi Wang.
Comprehensive genomic characterization of squamous cell lung cancers
Peter S. Hammerman;Doug Voet;Michael S. Lawrence;Douglas Voet.
Integrated Genomic Characterization of Papillary Thyroid Carcinoma
Nishant Agrawal;Rehan Akbani;B. Arman Aksoy;Adrian Ally.
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing
Marcin Imielinski;Alice H. Berger;Alice H. Berger;Peter S. Hammerman;Peter S. Hammerman;Bryan Hernandez.
Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34
Marjon van Slegtenhorst;Ronald de Hoogt;Caroline Hermans;Mark Nellist.
Caspase-3-Generated Fragment of Gelsolin: Effector of Morphological Change in Apoptosis
Srinivas Kothakota;Toshifumi Azuma;Toshifumi Azuma;Toshifumi Azuma;Christoph Reinhard;Christoph Reinhard;Christoph Reinhard;Anke Klippel;Anke Klippel;Anke Klippel.
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
Neal I. Lindeman;Philip T. Cagle;Mary Beth Beasley;Dhananjay Arun Chitale.
Journal of Thoracic Oncology (2013)
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer
A. Gordon Robertson;Jaegil Kim;Hikmat Al-Ahmadie;Joaquim Bellmunt.
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Mark G. Kris;Bruce E. Johnson;Lynne D. Berry;David J. Kwiatkowski.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: